Tumor-Infiltrating Lymphocyte (TIL) Therapy CMC — FDA and EMA Regulatory Framework for Ex Vivo Expansion

TIL therapy has achieved a regulatory milestone that few believed possible a decade ago — an FDA-approved autologous cell therapy with a manufacturing process that starts from a patient’s resected tumor, requires weeks of ex vivo expansion, and produces a drug product where the dose for each patient is unique. The CMC documentation for that product is among the most complex in pharmaceutical development: the starting material changes for every patient, the manufacturing process must accommodate starting material variability spanning an order of magnitude in TIL yield, and the potency assay must measure antitumor cytotoxic activity in a product where demonstrating correlation to autologous tumor cell killing is a regulatory expectation that cannot be met routinely at lot release.

A TIL CMC package that treats the manufacturing yield threshold and the sterility timeline as clinical operations details rather than defined regulatory specifications has left the two decisions CBER scrutinizes most closely undocumented.

Pre-REP and REP Manufacturing Go/No-Go Criteria — The Autologous TIL Process Parameters That CBER Expects as Documented CMC Specifications, Not Clinical Manufacturing Practices

The TIL manufacturing process runs through two defined expansion stages, each carrying process parameters that belong in 3.2.P.3 as critical process parameters with manufacturing ranges and in-process control criteria, not as background description. Pre-REP — the initial expansion — cultures tumor fragments in IL-2 at 6,000 IU/mL for 10 to 14 days to expand tumor-resident T cells, and the in-process control that determines whether manufacturing continues is a minimum TIL yield of at least 5×108 cells; lots falling short are, by definition, insufficient TIL outgrowth, and that threshold functions as a manufacturing go/no-go decision that must be documented as such, together with the patient disposition procedure for a failed run. The rapid expansion protocol (REP) that follows combines pre-REP TIL with irradiated feeder lymphocytes at a 200:1 feeder-to-TIL ratio, anti-CD3 antibody (OKT3) at 30 ng/mL, and IL-2 at 3,000 IU/mL over another 10 to 14 days, with a minimum fold-expansion criterion — at least 500-fold from the pre-REP input — serving as the batch success benchmark. The final drug product specification anchors all of this to a single dose-defining number: a minimum of 1×1010 TIL cells per dose, with viability of at least 70% by 7-AAD or trypan blue exclusion, alongside identity (CD3+ ≥85%), sterility, mycoplasma, and endotoxin testing. FDA’s Guidance for Human Somatic Cell Therapy and Gene Therapy (1998) establishes identity, purity, potency, and safety as the four required specification pillars, and a 3.2.P.3 section describing the pre-REP culture step without stating the minimum outgrowth go/no-go criterion and the disposition procedure for a failed run leaves CBER without the evidence that manufacturing failures are handled consistently rather than case by case.

Surrogate Potency Assay Qualification — Building the n=20 Correlation Dataset That Justifies Routine Lot Release Without Autologous Tumor Cell Killing

Autologous tumor cell killing is the direct mechanism-of-action potency test for TIL, but it is impractical for routine lot release for reasons that are structural rather than incidental: it requires viable autologous tumor cells that may not exist at the time of release, it depends on HLA typing to establish tumor-TIL antigen recognition, and its 4-hour cytotoxicity readout often cannot complete before the drug product’s release-to-infusion window closes. CBER’s Potency Tests for Cellular and Gene Therapy Products (2011) guidance permits a surrogate assay for routine release when that surrogate is qualified against the mechanism-of-action assay — and the qualification bar is specific: a correlation study measuring both the surrogate result (IFN-γ secretion at a defined OKT3 concentration, or CD107a degranulation percentage of CD8+ TIL under defined stimulation) and the autologous tumor cell killing result (specific lysis at an effector:target ratio of 10:1) across a minimum of 20 patient manufacturing lots, with the Pearson correlation coefficient required to reach at least 0.75 before the surrogate is accepted. The surrogate’s own inter-assay precision must independently clear a CV of 30% or below across multiple runs before it is fit for lot release use. A potency specification that lists the surrogate assay and its acceptance criterion but omits this correlation dataset is the single deficiency pattern CBER reviewers raise most consistently in this domain — the surrogate assay result means nothing as a release specification until the correlation to the actual antitumor mechanism has been established and quantified.

Sterility Testing Architecture and the 24-Hour Shelf Life Conflict — The Cryopreservation Hold Strategy and Rapid Sterility Method Options for Autologous TIL Release

USP <71> sterility testing requires 14 days of incubation before a sample can be declared sterile, and a TIL drug product with a shelf life of 24 to 48 hours after thaw cannot generate that result before administration — a direct conflict between the compendial sterility standard and the operational reality of autologous cell therapy timing that every TIL CMC package must resolve explicitly, not implicitly. CBER has accepted two structural responses. The first is a cryopreservation hold strategy: the manufactured TIL is cryopreserved at an intermediate step, post-REP and pre-formulation, and held in quarantine while the 14-day sterility result is pending on that intermediate, with final drug product formulation and release occurring only after a confirmed negative result — an approach that adds meaningful manufacturing time but produces a valid pre-release sterility result rather than an assumed one. The second is a validated rapid sterility method, such as an automated blood culture system with a 3-to-5-day turnaround, used as the lot release test if it has been validated as equivalent to or more sensitive than USP <71> for the organisms the compendial method specifies. A specification that cites USP <71> as the sterility test while the batch record shows a 24-hour release-to-infusion window is an internal contradiction CBER reviewers flag directly, and the request that follows asks not just for clarification but for the protocol governing what happens if a positive sterility result arrives after the drug product has already been administered.

The XGene TIL CMC Regulatory Architecture — Starting Material Specification, Manufacturing CPP/IPC Design, Potency Qualification, and Sterility Strategy for CBER BLA and EMA CAT Submissions

The XGene TIL CMC Regulatory Architecture is a structured CMC strategy for autologous TIL programs built around the reality that every patient’s starting material is unique and every specification must accommodate that variability without sacrificing regulatory rigor.

1. Tumor Tissue Starting Material Specification — Document the procurement, pathology qualification, and minimum pre-REP outgrowth yield criterion per 21 CFR 1271 and ICH Q5D, treating the resected tumor as a defined, qualified starting material rather than an uncharacterized clinical sample. 2. Manufacturing CPP and IPC Design — Fix pre-REP IL-2 concentration, REP OKT3 and feeder ratio parameters, and go/no-go yield criteria with documented patient disposition procedures for manufacturing failures. 3. Surrogate Potency Assay Qualification — Build the n≥20 lot correlation dataset against autologous tumor cell killing, clear the Pearson r ≥0.75 threshold, and independently validate the surrogate’s inter-assay precision (CV ≤30%). 4. Sterility Testing Architecture — Select and validate either the cryopreservation hold strategy or a rapid sterility method, documenting the regulatory basis for whichever approach replaces same-timeline USP <71> testing. 5. Lot Release Specification Assembly — Integrate the minimum cell number (≥1×1010), viability (≥70%), identity, potency, and safety criteria into the complete Module 3.2 release package.

The output is the CMC evidence package CBER and EMA CAT reviewers expect for an autologous TIL BLA or MAA where no two patient lots share a starting material.

FDA’s approval record for autologous cell therapies — anchored by Amtagvi (lifileucel, Iovance Biotherapeutics), the first FDA-approved autologous TIL therapy, approved in February 2024 for unresectable or metastatic melanoma — established the first regulatory precedent for TIL CMC covering tumor tissue starting material specifications, pre-REP/REP manufacturing documentation, surrogate potency assay qualification, and a sterility testing approach built for a compressed administration window. CBER’s Potency Tests guidance (2011) remains the foundational authority for the surrogate qualification requirement, and EMA’s ATMP guideline for advanced therapy medicinal products in clinical trials establishes the parallel manufacturing characterization and comparability expectations for TIL programs pursuing simultaneous FDA and EMA pathways.

Can you confirm today whether your TIL drug product specification in 3.2.P.5 includes a minimum cell number per dose specification, a surrogate potency assay with a pre-specified correlation qualification dataset against autologous tumor cell killing, and a documented sterility testing strategy that provides valid sterility results before drug product administration — not as a clinical practice exception, but as a defined regulatory CMC specification?